Hologic, Inc.

Report azionario NasdaqGS:HOLX

Capitalizzazione di mercato: US$16.9b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Hologic Crescita futura

Criteri Future verificati 1/6

Hologic prevede che gli utili e i ricavi cresceranno rispettivamente di 13.9% e 4.7% all'anno. Si prevede che l'EPS crescerà di 14.2% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 16.9% in 3 anni.

Informazioni chiave

13.9%

Tasso di crescita degli utili

14.21%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili16.1%
Tasso di crescita dei ricavi4.7%
Rendimento futuro del capitale proprio16.94%
Copertura analitica

Good

Ultimo aggiornamento06 Apr 2026

Aggiornamenti recenti sulla crescita futura

Articolo di analisi • Aug 04

Analysts Have Made A Financial Statement On Hologic, Inc.'s (NASDAQ:HOLX) Third-Quarter Report

Investors in Hologic, Inc. ( NASDAQ:HOLX ) had a good week, as its shares rose 2.2% to close at US$67.16 following the...

Recent updates

Aggiornamento della narrazione • Apr 10

HOLX: Pending 79 Cash Buyout And Hold Stance Will Guide Near-Term Trading

Analysts now view Hologic’s value as effectively unchanged, with a refreshed price framework still centered around $76.67 per share as they factor in the pending $79 per share cash acquisition and recent downgrades to Hold related to the transaction’s expected early February close. Analyst Commentary Recent research focuses heavily on the pending all cash acquisition at up to $79 per share and how that affects the risk and reward for current shareholders.
Aggiornamento della narrazione • Mar 26

HOLX: Pending 79 Cash Buyout And Hold Ratings Will Shape Near-Term Outcomes

Analysts now see Hologic's fair value edging to about $76.67 per share, with only minor tweaks to growth, margin and P/E inputs. They are also reflecting increased caution around the pending up to $79 per share cash acquisition by Blackstone and TPG, which has led to a shift in ratings to Hold.
Aggiornamento della narrazione • Mar 12

HOLX: Pending 79 Cash Buyout And Hold Stance Will Guide Near-Term Outcomes

Analysts have kept their average price target for Hologic broadly unchanged at about $76.60, noting only minor tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions as they factor in the pending $79 per share acquisition by Blackstone and TPG and recent rating changes to Hold. Analyst Commentary Recent research has shifted Hologic to more of a wait and see idea, as the pending buyout at up to $79 per share becomes the main anchor for valuation and expected outcomes.
Aggiornamento della narrazione • Feb 26

HOLX: Pending 79 Cash Buyout And Hold Rating Will Define Event Path

Analysts have adjusted their price target on Hologic to $79.00 per share, reflecting updated assumptions regarding a future P/E multiple and the pending $79 per share acquisition by funds managed by Blackstone and TPG. Analyst Commentary Recent research updates have shifted toward a more neutral stance on Hologic, with the pending acquisition at $79 per share now the main reference point for valuation rather than long term growth assumptions.
Aggiornamento della narrazione • Feb 11

HOLX: Buyout Terms And Neutral Ratings Will Shape Event-Driven Returns Through 2026

Analysts have trimmed their fair value estimate for Hologic to US$76.60 from about US$76.92, citing recent downgrades to Hold and Neutral, as the pending US$79 per share buyout by Blackstone and TPG narrows the expected upside. Analyst Commentary Recent research updates around Hologic largely reflect the pending all cash acquisition at US$79 per share, with several firms moving to more neutral stances as the share price tracks closer to the agreed takeout level.
Aggiornamento della narrazione • Jan 26

HOLX: Buyout Terms And Neutral Ratings Will Frame Returns Through 2026

Narrative Update The analyst fair value estimate for Hologic has edged up by about $0.50 per share as analysts align their targets more closely with the pending private equity acquisition price of up to $79. They are also updating assumptions around the discount rate, modest revenue growth, and future P/E.
Aggiornamento della narrazione • Jan 12

HOLX: Buyout Deal Terms And Rating Downgrades Will Guide Trading Through 2026

Our updated analyst price target for Hologic edges down slightly to about $76.42 per share. This reflects that analysts now anchor their views more tightly to the proposed Blackstone and TPG takeout value of up to $79 per share and the recent wave of rating downgrades to Neutral or Hold around that deal.
Aggiornamento della narrazione • Dec 18

HOLX: Buyout Terms And Neutral Ratings Will Shape Trading Through 2026

We trim our Hologic price target slightly to approximately $76.50, as analysts coalesce around the proposed Blackstone and TPG takeout valuation of up to $79.00 per share and see limited upside beyond the agreed acquisition terms. Analyst Commentary Street research following the announced takeout has converged around the proposed valuation, with most firms adjusting ratings and targets to reflect a view that the deal price largely caps near term upside.
Aggiornamento della narrazione • Dec 04

HOLX: Buyout Deal And Neutral Ratings Will Define Shares Through 2026

The analyst price target for Hologic has inched higher by approximately $0.33 to $76.50, as analysts factor in slightly stronger long term growth and margin assumptions while anchoring valuation to the proposed Blackstone and TPG takeout price near $79 per share. Analyst Commentary Analyst reaction to the proposed Blackstone and TPG acquisition has been mixed, with most firms converging around price targets in the mid to high $70s and resetting ratings to more neutral stances as upside becomes more constrained by the agreed takeout price.
Aggiornamento della narrazione • Nov 20

HOLX: Acquisition Agreement With Blackstone and TPG Will Shape Stock Outlook Through 2026

Hologic’s analyst price target has increased modestly from $75.08 to $76.17 per share. Analysts view the proposed $79 per share acquisition by Blackstone and TPG as providing a fair valuation and setting a near-term ceiling for the stock.
Aggiornamento della narrazione • Nov 05

HOLX: Downgrades And Buyout Agreement Will Shift Near-Term Share Performance

Analysts have modestly increased their price target for Hologic from approximately $73.54 to $75.08. They cite the recently announced acquisition by Blackstone and TPG as supportive of current valuation levels, given the company's operating challenges and outlook.
Aggiornamento della narrazione • Oct 22

Analysts Raise Hologic Targets Amid Strong Results and Positive Acquisition Momentum

Hologic's analyst price target has increased by $1.11, as analysts cite improving financial performance and the impact of the recent acquisition agreement as key factors that support the higher valuation. Analyst Commentary Bullish Takeaways Bullish analysts increased their price targets, pointing to Hologic's improved financial results and raised full-year guidance amid strong recent revenue and EPS performance.
Aggiornamento della narrazione • Sep 28

Preventive Healthcare And Advanced Diagnostics Will Shape Future Markets

Despite strong quarterly outperformance, higher 2025 guidance, and increased buyout speculation, Hologic's consensus analyst price target was modestly reduced from $73.87 to $72.43 as fiscal 2025 estimates were recalibrated to reflect current demand trends and tariff expectations. Analyst Commentary Strong revenue and EPS outperformance in the recent quarter, with management raising full-year 2025 guidance.
Articolo di analisi • Sep 13

Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Aggiornamento della narrazione • Sep 05

Preventive Healthcare And Advanced Diagnostics Will Shape Future Markets

Despite strong Q3 results, raised FY25 guidance, and increased investor interest from buyout speculation, Hologic’s consensus price target remains unchanged at $73.87 as estimates are now better aligned with actual demand and tariff risks. Analyst Commentary Raised FY25 guidance and Q3 results substantially beat revenue and EPS expectations, demonstrating robust operational performance.
Articolo di analisi • Aug 04

Analysts Have Made A Financial Statement On Hologic, Inc.'s (NASDAQ:HOLX) Third-Quarter Report

Investors in Hologic, Inc. ( NASDAQ:HOLX ) had a good week, as its shares rose 2.2% to close at US$67.16 following the...
Articolo di analisi • Jul 19

Is Hologic, Inc. (NASDAQ:HOLX) Trading At A 38% Discount?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Hologic fair value estimate is US$103 Hologic is estimated to...
Articolo di analisi • Jul 01

The Price Is Right For Hologic, Inc. (NASDAQ:HOLX)

With a price-to-earnings (or "P/E") ratio of 26.1x Hologic, Inc. ( NASDAQ:HOLX ) may be sending bearish signals at the...
Articolo di analisi • Jun 13

Is Hologic (NASDAQ:HOLX) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • May 06

Hologic: Soft Performance, But Cheap Enough

Summary Hologic, Inc.'s appeal has increased due to reduced debt, serial buybacks, and modest valuations, despite recent negative organic growth and pricey acquisitions. The company has shown solid long-term growth, reducing leverage significantly and buying back shares, but recent performance has been soft with flattish sales and earnings. Despite a slight cut in earnings guidance and soft organic growth, Hologic's shares now trade at attractive multiples with very manageable leverage. While cautious due to recent underperformance and expensive acquisitions, I remain upbeat on HOLX stock and plan to add to my long position. Read the full article on Seeking Alpha
Seeking Alpha • Jan 17

Hologic: Reasonably, But Not Compellingly Valued

Summary Hologic, Inc. is down approximately 20% from recent highs despite strong quarterly results. The company continues to grow organically and via a series of 'bolt-on' acquisitions.  Management also recently added significantly to the company's stock buyback authorization. An updated analysis around Hologic, Inc. follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Oct 28

Hologic: Continued Room Amidst Bolt-On M&A Efforts

Summary Hologic, Inc.'s focus on women's health and strategic M&A, despite pandemic headwinds, positions it for continued growth with a projected $4 billion revenue in 2024. Trading at 20 times earnings, Hologic's quality and growth potential justify its valuation, with shares having risen 10% since May. The company maintains solid organic growth, reducing net debt and executing strategic acquisitions like Endomagnetics and Gynesonics, enhancing its market position. With pandemic-related diagnostics sales declining, Hologic's consistent earnings and strategic moves make it a compelling investment, despite shares not being cheap. Read the full article on Seeking Alpha
Seeking Alpha • Aug 27

Hologic Has A Lot Of Fine Qualities, But A Discount Valuation Isn't Among Them

Summary Hologic has been outperforming peers but underperforming the broader medical device sector, with shares up about 5% since my last analysis. Fiscal Q3 results showed consistent beats in Diagnostics, Breast Health, and Surgical segments, but Skeletal Health faced setbacks due to supplier issues. Management has continued to optimize the pandemic-driven surge in Panther placements, with the BV CV/TV panel growing to the second-largest panel in the company's portfolio. Hologic has been a share gainer in molecular diagnostics and is active in M&A, but long-term 5% to 7% revenue growth targets may be too challenging. Long-term revenue growth around 5%, near-term EBITDA margins in the low-30%s, and long-term FCF growth of around 6% support today's valuation and single-digit returns, but Hologic doesn't stand out as undervalued. Read the full article on Seeking Alpha

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:HOLX - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
9/30/20284,6989621,1441,1798
9/30/20274,4598351,0741,15115
9/30/20264,2367371,0141,08914
12/27/20254,1275449571,098N/A
9/27/20254,1015669051,057N/A
6/28/20254,0395579171,069N/A
3/29/20254,0275579701,132N/A
12/28/20244,0397441,1051,255N/A
9/28/20244,0307901,1451,285N/A
6/29/20243,9887021,0151,177N/A
3/30/20243,9614679491,104N/A
12/30/20233,9695158591,018N/A
9/30/20234,0304569011,051N/A
7/1/20234,038484832961N/A
4/1/20234,057753841959N/A
12/31/20224,4669901,6961,815N/A
9/24/20224,8631,3021,9992,126N/A
6/25/20225,2261,5122,2832,423N/A
3/26/20225,3921,5522,5982,755N/A
12/25/20215,4941,7162,0682,245N/A
9/25/20215,6321,8722,1462,330N/A
6/26/20215,6632,0382,1082,307N/A
3/27/20215,3171,9071,6771,867N/A
12/26/20204,5361,3841,2631,433N/A
9/26/20203,7761,115740897N/A
6/27/20203,295497573702N/A
3/28/20203,325453518643N/A
12/28/20193,38784536659N/A
9/28/20193,367-204N/A650N/A
6/29/20193,315-30N/A634N/A
3/30/20193,287-11N/A705N/A
12/29/20183,258-419N/A668N/A
9/29/20183,218-111N/A733N/A
6/30/20183,207-79N/A667N/A
3/31/20183,189-132N/A21N/A
12/30/20173,1161,076N/A8N/A
9/30/20173,059756N/A8N/A
7/1/20172,983765N/A70N/A
4/1/20172,894790N/A729N/A
12/31/20162,872332N/A796N/A
9/24/20162,833331N/A798N/A
6/25/20162,809264N/A802N/A
3/26/20162,785208N/A797N/A
12/26/20152,747187N/A804N/A
9/26/20152,705132N/A797N/A
6/27/20152,641135N/A685N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di HOLX ( 13.9% all'anno) è superiore al tasso di risparmio ( 3.4% ).

Guadagni vs Mercato: Si prevede che gli utili di HOLX ( 13.9% all'anno) cresceranno più lentamente rispetto al mercato US ( 16.7% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di HOLX cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di HOLX ( 4.7% all'anno) crescerà più lentamente rispetto al mercato US ( 11.7% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di HOLX ( 4.7% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di HOLX sarà basso tra 3 anni ( 16.9 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/04/06 20:54
Prezzo dell'azione a fine giornata2026/04/06 00:00
Utili2025/12/27
Utili annuali2025/09/27

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Hologic, Inc. è coperta da 25 analisti. 15 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
David ToungArgus Research Company
Charles ButlerBarclays
Charley JonesBarrington Research Associates, Inc.